

Deferred registration: Quotient Sciences code: QSC303996

Submission date 04/05/2026	Recruitment status Recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 18/05/2026	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 18/05/2026	Condition category Other	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)

Principal investigator

Contact name

Dr Nand Singh

Contact details

Mere Way, Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 01159749000
recruitment@weneedyou.co.uk

Type(s)

Public, Scientific

Contact name

None Clinical Study Director

Contact details

Orionintie 1
Espoo
Finland
FI-0220

+358 10 4261
clinicaltrials@orionpharma.com

Additional identifiers

Integrated Research Application System (IRAS)
1013675

CRO code
QSC303996

Study information

Scientific Title
Deferred registration: Quotient Sciences code: QSC303996

Study objectives

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required
Ethics approval required

Ethics approval(s)
submitted 17/03/2026, London – Bridge Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 0207 104 8387; londonbridge.rec@hra.nhs.uk), ref: 26/LO/0180

Primary study design
Interventional

Allocation
Randomized controlled trial

Masking
Open (masking not used)

Control
Uncontrolled

Assignment
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Purpose
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Study type(s)

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)

1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)

Completion date

10/08/2026

Eligibility

Key inclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed

Yes

Age group

Adult

Lower age limit

25 years

Upper age limit

55 years

Sex

Male

Total final enrolment

0

Key exclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment

15/05/2026

Date of final enrolment

10/08/2026

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**Quotient Sciences Limited**

Mere Way, Ruddington Fields

Ruddington

Nottingham

England

NG11 6JS

Sponsor information**Organisation**

Orion Corporation (Finland)

ROR

<https://ror.org/0296s4x19>

Funder(s)**Funder type****Funder Name**

Orion Corporation

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available